Author | Julio Fernandez, PharmD


NCCN's new lung cancer guidelines called a useful reference

February 11, 2008

NCCN's new guidelines for nonsmall cell lung cancer contain new recommendations relating to drug therapy.

FDA grapples with curbing IL drug container errors

February 05, 2007

Last July, an Institute of Medicine (IOM) report estimated that, on average, a hospital patient is subject to at least one medication error per day, although error rates vary by hospital and most do not lead to injury. The report urged the Food & Drug Administration to work with other agencies and healthcare providers to address drug labeling and packaging to minimize errors. In response to this recommendation, the FDA held a one-day public workshop last month to discuss how to improve the labeling of intravenous drug containers.

FDA approves new drug for schizophrenia

January 22, 2007

The Food & Drug Administration recently approved paliperidone (Invega, Janssen, L.P.), an atypical antipsychotic, for the treatment of schizophrenia, a disease that affects more than two million Americans. It is the first new treatment for schizophrenia to be approved since 2003.

Does nicotine replacement therapy hurt ICU patients?

December 11, 2006

A recent study by researchers at the Mayo Clinic College of Medicine has raised questions about the safety of administering nicotine replacement therapy (NRT) to smokers in the intensive care unit (ICU). Until now, use of NRT was not thought to be associated with serious adverse events. In fact, the Agency for Healthcare Research & Quality (AHRQ) recommends smoking cessation treatment for hospitalized patients.